This section describes the usefulness of CADM1 as a biomarker to evaluate the disease progression and severity in several diseases, such as ATLL [86,87], cervical cancer [88], and chronic kidney disease [89]. This evidence concerns the gene CADM1 and adult T-cell leukemia/lymphoma.